Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2017 - Product Image

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2017

  • ID: 4337663
  • Report
  • 119 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AptaTargets SL
  • Biomedica Management Corp
  • EyeGene Inc
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • NovImmune SA
  • MORE
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2017

Summary:

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 39 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 10, 3, 16 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Immunology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Pulmonary Inflammation, Breast Cancer, Inflammation, Inflammatory Bowel Disease, Liver Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Atherosclerosis, Autoimmune Hepatitis, Drug Addiction, Kidney Disease, Kidney Fibrosis, Rheumatoid Arthritis, Sepsis, Soft Tissue Sarcoma, Traumatic Brain Injury, Acne Vulgaris, Acute Ischemic Stroke, Acute Lung Injury, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Bacterial Sepsis, Burns, Cervical Cancer, Crohn's Disease (Regional Enteritis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Epilepsy, Escherichia coli Infections, Follicular Lymphoma, Globoid Cell Leukodystrophy (Krabbe Disease), Hearing Disorders, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Ischemia Reperfusion Injury, Keratoconjunctivitis sicca (Dry Eye), Leishmaniasis (Kala-Azar), Listeriosis, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Sclerosis, Necrotizing Enterocolitis, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Hodgkin Lymphoma, Opium Withdrawal Syndrome, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peanut Allergy, Phlebovirus Infections, Post-Traumatic Stress Disorder (PTSD), Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pseudomonas aeruginosa Infections, Recurrent Glioblastoma Multiforme (GBM), Rosacea, Secondary Progressive Multiple Sclerosis (SPMS), Septic Shock, Trauma, Wounds, Xerostomia and Zika Virus Infections.

The latest report Toll Like Receptor 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AptaTargets SL
  • Biomedica Management Corp
  • EyeGene Inc
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • NovImmune SA
  • MORE
Introduction

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development

AptaTargets SL

Batu Biologics Inc

Biomedica Management Corp

Eisai Co Ltd

eTheRNA Immunotherapies NV

EyeGene Inc

Formune SL

GlaxoSmithKline Plc

Harbor Therapeutics Inc

Immune Design Corp

Immunovo BV

Kyorin Pharmaceutical Co Ltd

NovImmune SA

Sanofi

TaiwanJ Pharmaceuticals Co Ltd

Vascular Biogenics Ltd

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles

ApTOLL - Drug Profile

AyuV-25 - Drug Profile

Biologic to Agonize TLR4 for Drug Addiction - Drug Profile

C-34 - Drug Profile

CIA-05 - Drug Profile

CMB-305+G-100 - Drug Profile

CRX-526 - Drug Profile

DMT-210 - Drug Profile

Drugs to Agonize TLR4 for Oncology - Drug Profile

ECF-843 - Drug Profile

ECI-006 - Drug Profile

EDA-HPVE7 - Drug Profile

eritoran tetrasodium - Drug Profile

G-100 - Drug Profile

Glyco-23 - Drug Profile

GSK-1795091 - Drug Profile

HE-3286 - Drug Profile

hp-91 - Drug Profile

ibudilast - Drug Profile

ISAS-01 - Drug Profile

JKB-117 - Drug Profile

JKB-119 - Drug Profile

JKB-121 - Drug Profile

naltrexone hydrochloride - Drug Profile

NI-0101 - Drug Profile

P-13 - Drug Profile

P-16 - Drug Profile

P-7 - Drug Profile

P-MAPA - Drug Profile

PEPA-10 - Drug Profile

rabeximodum - Drug Profile

SAR-439794 - Drug Profile

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile

Small Molecules to Antagonize TLR2 and TLR4 for Immunology and Inflammation - Drug Profile

Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile

TWJ-201 - Drug Profile

VB-201 - Drug Profile

VB-703 - Drug Profile

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indications, H2

Number of Products under Development by Indications, H2 2017 (Contd..1), H2

Number of Products under Development by Indications, H2 2017 (Contd..2), H2

Number of Products under Development by Indications, H2 2017 (Contd..3), H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1)

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Products under Development by Companies, H2 2017 (Contd..4), H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by AptaTargets SL, H2

Pipeline by Batu Biologics Inc, H2

Pipeline by Biomedica Management Corp, H2

Pipeline by Eisai Co Ltd, H2

Pipeline by eTheRNA Immunotherapies NV, H2

Pipeline by EyeGene Inc, H2

Pipeline by Formune SL, H2

Pipeline by GlaxoSmithKline Plc, H2

Pipeline by Harbor Therapeutics Inc, H2

Pipeline by Immune Design Corp, H2

Pipeline by Immunovo BV, H2

Pipeline by Kyorin Pharmaceutical Co Ltd, H2

Pipeline by NovImmune SA, H2

Pipeline by Sanofi, H2

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2

Pipeline by Vascular Biogenics Ltd, H2

Dormant Products, H2

Dormant Products, H2 2017 (Contd..1), H2

Dormant Products, H2 2017 (Contd..2), H2

Discontinued Products, H2

List of Figures:

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AptaTargets SL
  • Batu Biologics Inc
  • Biomedica Management Corp
  • Eisai Co Ltd
  • eTheRNA Immunotherapies NV
  • EyeGene Inc
  • Formune SL
  • GlaxoSmithKline Plc
  • Harbor Therapeutics Inc
  • Immune Design Corp
  • Immunovo BV
  • Kyorin Pharmaceutical Co Ltd
  • NovImmune SA
  • Sanofi
  • TaiwanJ Pharmaceuticals Co Ltd
  • Vascular Biogenics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll